Literature DB >> 24368091

Bisphosphonate treatment for children with disabling conditions.

Alison M Boyce1, Laura L Tosi2, Scott M Paul3.   

Abstract

Fractures are a frequent source of morbidity in children with disabling conditions. The assessment of bone density in this population is challenging, because densitometry is influenced by dynamic forces affecting the growing skeleton and may be further confounded by positioning difficulties and surgical hardware. First-line treatment for pediatric osteoporosis involves conservative measures, including optimizing the management of underlying conditions, maintaining appropriate calcium and vitamin D intake, encouraging weight-bearing physical activity, and monitoring measurements of bone mineral density. Bisphosphonates are a class of medications that increase bone mineral density by inhibiting bone resorption. Although bisphosphonates are commonly prescribed for treatment of adult osteoporosis, their use in pediatric patients is controversial because of the lack of long-term safety and efficacy data.
Copyright © 2014 American Academy of Physical Medicine and Rehabilitation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24368091      PMCID: PMC4037384          DOI: 10.1016/j.pmrj.2013.10.009

Source DB:  PubMed          Journal:  PM R        ISSN: 1934-1482            Impact factor:   2.298


  102 in total

1.  Recovery from osteoporosis through skeletal growth: early bone mass acquisition has little effect on adult bone density.

Authors:  Rachel I Gafni; Edward F McCarthy; Tracy Hatcher; Jodi L Meyers; Nozomu Inoue; Chitra Reddy; Martina Weise; Kevin M Barnes; Veronica Abad; Jeffrey Baron
Journal:  FASEB J       Date:  2002-03-26       Impact factor: 5.191

2.  Exercise-induced bone gain is due to enlargement in bone size without a change in volumetric bone density: a peripheral quantitative computed tomography study of the upper arms of male tennis players.

Authors:  H Haapasalo; S Kontulainen; H Sievänen; P Kannus; M Järvinen; I Vuori
Journal:  Bone       Date:  2000-09       Impact factor: 4.398

Review 3.  The unique features of traumatic brain injury in children. review of the characteristics of the pediatric skull and brain, mechanisms of trauma, patterns of injury, complications, and their imaging findings--part 2.

Authors:  Pedro S Pinto; Avner Meoded; Andrea Poretti; Aylin Tekes; Thierry A G M Huisman
Journal:  J Neuroimaging       Date:  2012-02-03       Impact factor: 2.486

4.  Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.

Authors:  R Lala; P Matarazzo; S Bertelloni; F Buzi; F Rigon; C de Sanctis
Journal:  Acta Paediatr       Date:  2000-02       Impact factor: 2.299

Review 5.  Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.

Authors:  David W Dempster; Cheryl L Lambing; Paul J Kostenuik; Andreas Grauer
Journal:  Clin Ther       Date:  2012-03       Impact factor: 3.393

6.  Does body size account for gender differences in femur bone density and geometry?

Authors:  A C Looker; T J Beck; E S Orwoll
Journal:  J Bone Miner Res       Date:  2001-07       Impact factor: 6.741

7.  The development of metaphyseal cortex--implications for distal radius fractures during growth.

Authors:  F Rauch; C Neu; F Manz; E Schoenau
Journal:  J Bone Miner Res       Date:  2001-08       Impact factor: 6.741

8.  Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.

Authors:  H Plotkin; F Rauch; N J Bishop; K Montpetit; J Ruck-Gibis; R Travers; F H Glorieux
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

9.  Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.

Authors:  Margaret Zacharin; John Bateman
Journal:  J Pediatr Endocrinol Metab       Date:  2002-02       Impact factor: 1.634

10.  Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.

Authors:  E Aström; S Söderhäll
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

View more
  14 in total

1.  Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?

Authors:  Adele L Boskey; Josephine Marino; Lyudmila Spevak; Nancy Pleshko; Stephen Doty; Erin M Carter; Cathleen L Raggio
Journal:  Clin Orthop Relat Res       Date:  2015-08       Impact factor: 4.176

Review 2.  An update on childhood bone health: mineral accrual, assessment and treatment.

Authors:  Aviva B Sopher; Ilene Fennoy; Sharon E Oberfield
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-02       Impact factor: 3.243

3.  Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.

Authors:  Diana Olvera; Rachel Stolzenfeld; Joan C Marini; Michelle S Caird; Kenneth M Kozloff
Journal:  J Bone Miner Res       Date:  2018-05-07       Impact factor: 6.741

4.  Patterns of bisphosphonates utilization in patients under age 45 in a large cohort of commercial insurance beneficiaries in the United States.

Authors:  Jing Xie; Angela Tong; Seoyoung C Kim
Journal:  PLoS One       Date:  2015-01-22       Impact factor: 3.240

5.  Local vs. systemic administration of bisphosphonates in rat cleft bone graft: A comparative study.

Authors:  Christine Hong; Alison Quach; Lawrence Lin; Jeffrey Olson; Taewoo Kwon; Olga Bezouglaia; Jaime Tran; Michael Hoang; Kimberly Bui; Reuben H Kim; Sotirios Tetradis
Journal:  PLoS One       Date:  2018-01-05       Impact factor: 3.240

6.  The relationship of bone mineral density and vitamin D levels with steroid use and ambulation in patients with Duchenne muscular dystrophy.

Authors:  Filiz Meryem Sertpoyraz; Bedile İrem Tiftikçioğlu
Journal:  Turk J Phys Med Rehabil       Date:  2019-08-20

7.  Bisphosphonate use in children with cerebral palsy.

Authors:  Tim Hurley; Zunera Zareen; Philip Stewart; Ciara McDonnell; Denise McDonald; Eleanor Molloy
Journal:  Cochrane Database Syst Rev       Date:  2021-07-05

8.  Evaluation of the effectiveness of robotic gait training and gait-focused physical therapy programs for children and youth with cerebral palsy: a mixed methods RCT.

Authors:  Lesley Wiart; Rhonda J Rosychuk; F Virginia Wright
Journal:  BMC Neurol       Date:  2016-06-02       Impact factor: 2.474

Review 9.  Different clinical presentation and management of temporal bone fibrous dysplasia in children.

Authors:  Józef Mierzwiński; Justyna Kosowska; Justyna Tyra; Karolina Haber; Maria Drela; Dariusz Paczkowski; Paweł Burduk
Journal:  World J Surg Oncol       Date:  2018-01-15       Impact factor: 2.754

10.  Lower incidence of fracture after IV bisphosphonates in girls with Rett syndrome and severe bone fragility.

Authors:  Anne-Sophie Lambert; Anya Rothenbuhler; Perrine Charles; Sylvie Brailly-Tabard; Séverine Trabado; Elisabeth Célestin; Emmanuel Durand; Isabelle Fontaine; Lotfi Miladi; Philippe Wicart; Nadia Bahi-Buisson; Agnès Linglart
Journal:  PLoS One       Date:  2017-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.